Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.44 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508729 | 1.00 | CYP1A2 (0.63) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL28327989 | 0.86 | MAPT (0.63) | CYP1A2CYP2C9HPGDHSD17B10LMNA | |
| SCHEMBL3553668 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL10348307 | 0.85 | LMNA (0.50) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL26622156 | 0.85 | LMNA (0.54) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL2787937 | 0.84 | TSHR (0.53) | CYP1A2CYP2C9HPGDHSD17B10LMNA | |
| SCHEMBL513796 | 0.84 | LMNA (0.49) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL1448525 | 0.84 | TSHR (0.49) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL842358 | 0.84 | MAPK1 (0.49) | CYP1A2CYP2C9HPGDHSD17B10LMNA | |
| SCHEMBL5315806 | 0.81 | HSD17B10 (0.63) | CYP1A2CYP2C9HPGDHSD17B10APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12577244-B2 | Heterocyclic compound and harmful arthropod-controlling composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240010648-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-01-11 | — | — | US | disclosed |
| CN-1391565-A | Benzophenones as reverse transcriptase inhibitors | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
| US-20020127577-A1 | Bioactive sensors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-09-12 | — | — | US | disclosed |
| EP-1238970-A1 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | disclosed |
| EP-1185869-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | Graffinity Pharmaceutical Design GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000073796-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) | 2000-12-07 | — | — | WO | disclosed |
| US-4020169-A | FROM ARYL IODIDE OR BROMIDE AND TRIFLUOROMETHYL THIO COPPER | MERCK & CO., INC. (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577244-B2 | Heterocyclic compound and harmful arthropod-controlling composition containing same | CYC1, COX6C, CBR3 | CYP1A2 251/4885CYP2C9 371/4885HPGD 3189/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | CYP1A2 549/4885CYP2C9 443/4885HPGD 2345/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | CYP1A2 2169/4885CYP2C9 2725/4885HPGD 1182/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | CYP1A2 585/4885CYP2C9 418/4885HPGD 2085/4885 |
| US-20240010648-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | C3AR1, C5, NR4A3 | CYP1A2 126/4885CYP2C9 354/4885HPGD 2853/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | CYP1A2 549/4885CYP2C9 443/4885HPGD 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.